Why would a 40-year-old woman have an elevated sex‑hormone‑binding globulin level of approximately 174 nmol/L?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Elevated Sex Hormone-Binding Globulin in a 40-Year-Old Woman

An SHBG level of 174 nmol/L in a 40-year-old woman most likely indicates hyperthyroidism, particularly Graves' disease or toxic nodular goiter, and warrants immediate thyroid function testing with TSH, free T4, and free T3.

Primary Cause: Hyperthyroidism

Hyperthyroidism is the most common pathologic cause of markedly elevated SHBG in this age group. 1, 2

  • In overt hyperthyroidism (Graves' disease or toxic nodular goiter), mean SHBG concentrations reach 120–142 nmol/L compared to the normal female range of approximately 48 nmol/L. 2
  • SHBG elevation reflects increased hepatic synthesis driven by excess thyroid hormone and serves as a peripheral tissue marker of thyroid hormone effect at the liver level. 2
  • The degree of SHBG elevation correlates with the severity of hyperthyroidism—patients with total T4 >15 µg/dL show elevated SHBG in 82% of cases, whereas those with isolated T3 elevation show elevation in only 25%. 3
  • SHBG is particularly useful for distinguishing TSH-secreting pituitary adenomas from thyroid hormone resistance, as both conditions produce elevated free T4 with inappropriately normal TSH, but TSH-secreting adenomas cause clinical thyrotoxicosis with elevated SHBG and resting energy expenditure. 1

Diagnostic Algorithm

Step 1: Measure TSH, free T4, and free T3 immediately. 1, 4

  • If TSH is suppressed (<0.01 mU/L) with elevated free T4 and/or free T3, overt hyperthyroidism is confirmed. 4
  • If TSH is inappropriately normal or elevated despite high free T4, consider TSH-secreting pituitary adenoma (requires pituitary MRI and alpha-subunit measurement) or thyroid hormone resistance (requires genetic testing). 1

Step 2: Assess cardiovascular risk immediately. 4, 5

  • Check resting heart rate and obtain a 12-lead ECG to screen for atrial fibrillation, which is the primary driver of morbidity and mortality in thyrotoxicosis. 5
  • Patients with free T4 levels 2–3× the upper limit of normal and those over age 60 face the highest risk for serious cardiac events including embolic stroke. 5

Step 3: Determine the etiology of hyperthyroidism. 4

  • Measure TSH-receptor antibodies (TRAb), which provide near-100% sensitivity and specificity for Graves' disease. 4
  • If TRAb is unavailable or negative, perform radioactive iodine uptake and thyroid scintigraphy; diffuse uptake indicates Graves' disease, whereas focal uptake suggests toxic nodular disease. 4

Secondary Causes to Consider

Estrogen Excess

  • Exogenous estrogen (oral contraceptives, hormone replacement therapy) or pregnancy increases TBG and SHBG synthesis. 1, 6
  • Combined oral contraceptives containing third-generation progestins, cyproterone acetate, or drospirenone produce higher SHBG elevations than second-generation formulations. 6
  • However, estrogen-induced SHBG elevation is typically modest (not reaching 174 nmol/L) and occurs in the context of known estrogen exposure. 6

Hepatic Cirrhosis

  • Cirrhosis in men causes elevated SHBG due to altered hepatic synthetic function and estrogen metabolism. 7
  • This is less common in premenopausal women and would be accompanied by other signs of liver disease. 7

Medications

  • Anticonvulsants (phenytoin, carbamazepine) can increase SHBG through hepatic enzyme induction. 7
  • 5-fluorouracil, perphenazine, and some narcotics may elevate TBG and SHBG. 1

Critical Pitfall to Avoid

Do not assume elevated SHBG is benign or attribute it solely to estrogen status without excluding hyperthyroidism. 1, 2

  • Subclinical hyperthyroidism (suppressed TSH with normal free T4/T3) typically shows normal SHBG levels despite abnormal TSH, because the pituitary responds more sensitively than the liver to mild thyroid hormone changes. 2
  • An SHBG of 174 nmol/L indicates overt tissue exposure to excess thyroid hormone and demands urgent evaluation. 2, 3
  • Untreated overt hyperthyroidism carries high risk for atrial fibrillation, embolic stroke, osteoporosis, and cardiovascular collapse. 5

Management Once Hyperthyroidism is Confirmed

Initiate methimazole 15–20 mg once daily immediately (dose titrated to the degree of T3 elevation). 4

  • Begin a beta-blocker (e.g., propranolol, atenolol) if resting heart rate exceeds 90 bpm or if the patient has palpitations, tremor, or cardiovascular disease. 4
  • Obtain baseline complete blood count and liver function tests before starting methimazole. 4
  • Recheck free T4 and total T3 at week 4, then every 4–8 weeks until euthyroidism is achieved. 4
  • SHBG will normalize once the patient becomes euthyroid, confirming adequate treatment response. 2, 3

Additional Context on SHBG Physiology

  • Normal female SHBG ranges from approximately 30–60 nmol/L, with a mean around 48 nmol/L. 2, 8
  • SHBG is inversely correlated with insulin resistance, obesity (especially central adiposity), and androgen excess. 8, 9
  • Low SHBG (<30 nmol/L) is a biomarker of metabolic syndrome and polycystic ovary syndrome, whereas high SHBG (>100 nmol/L) in the absence of estrogen therapy strongly suggests hyperthyroidism. 2, 9

References

Guideline

hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the american thyroid association and american association of clinical endocrinologists.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2011

Guideline

Management of Overt Graves’ Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Elevated Free Thyroxine with Suppressed TSH

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.